Investing
Bio-Techne names new President for Diagnostics, Genomics
© Reuters.
MINNEAPOLIS – Bio-Techne (NASDAQ:) Corporation (NASDAQ:TECH), a global life sciences company, has appointed Matthew F. McManus as President of its Diagnostics and Genomics Segment, starting January 8, 2024. The announcement comes as part of a leadership transition that will see the current Chief Operating Officer, Kim Kelderman, step into the role of Chief Executive Officer on February 1, 2024.
Dr. McManus brings over 20 years of experience in the life sciences industry to his new position. His recent tenure includes serving as the Executive Vice President and Chief Operating Officer at Azenta, overseeing the company’s Life Sciences Products, Services, and commercial operations. He has a history with Bio-Techne, having previously led the company’s Molecular Diagnostics Division after Bio-Techne acquired Asuragen, where Dr. McManus was President and CEO.
His academic credentials are notable, with an M.D. and Ph.D. from the University of Pennsylvania School of Medicine, an MBA from Boston College, and a B.A. in Economics from the College of the Holy Cross. Additionally, he is currently the Chairman of the Board of Directors for ANSA, a firm involved in gene synthesis and cell & gene therapy markets.
Kim Kelderman expressed confidence in Dr. McManus’s appointment, stating his prior success at Bio-Techne and his extensive experience in the life sciences sector position him perfectly to lead the Diagnostics and Genomics Segment into its next growth phase.
Bio-Techne specializes in the development, manufacture, and sale of innovative and high-quality life science reagents, instruments, and services for research, diagnostics, and bioprocessing. The company’s commitment to providing high-quality products and services has made it a trusted partner in the global life sciences community.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here